tiprankstipranks
Trending News
More News >
Rein Therapeutics (RNTX)
NASDAQ:RNTX
US Market

Rein Therapeutics (RNTX) Income Statement

Compare
1,208 Followers

Rein Therapeutics Income Statement

Last quarter (Q3 2025), Rein Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Rein Therapeutics's net income was $-5.58M. See Rein Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 65.11M$ 16.28K$ 27.65K$ 26.61K$ 20.50K
Depreciation and Amortization
$ 63.00K$ 119.00$ 169.00$ 121.00$ 163.00
EBITDA
$ -28.05M$ -15.23K$ -27.48K$ -26.48K$ -20.33K
Operating Income
$ -65.11M$ -16.28K$ -27.65K$ -26.61K$ -20.50K
Other Income/Expenses
$ 800.00K$ 544.00$ 318.00$ 441.00$ -661.00
Pretax Income
$ -64.31M$ -15.73K$ -27.33K$ -26.16K$ -21.16K
Net Income
$ -62.88M$ -15.73K$ -27.33K$ -26.16K$ -21.16K
Per Share Metrics
Basic EPS
$ -3.51$ -3.42$ -6.02$ -5.89$ 0.00
Diluted EPS
$ -3.51$ -3.42$ -6.02$ -5.89$ 0.00
Weighted Average Shares Outstanding
17.94K 4.60K 4.54K 4.44K-
Weighted Average Shares Outstanding (Diluted)
17.94K----
Currency in USD

Rein Therapeutics Earnings and Revenue History